secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001628280-25-047920
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences Q3 net loss $21.8M ($1.84/sh); PBGENE-HBV doses Cohort 3, PBGENE-DMD IND on track
--------------------------------------------------------------------------------

- Net loss of $21.8M ($1.84/sh) vs $16.4M ($2.25/sh) in Q3 2024.
- Revenue <$0.1M, down from $0.6M YoY; R&D $13.4M, G&A $7.3M.
- Cash $71.2M; expected runway into H2 2027 via cost cuts and potential near-term CAR T payments.
- PBGENE-HBV Phase 1 dosing Cohort 3; late-breaking oral at AASLD on Nov 10.
- PBGENE-DMD IND filing expected end-2025; Phase 1 start H1 2026, initial data H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000162828025047920/0001628280-25-047920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000162828025047920/dtil-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-047920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer